Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

N0590200

Nicotine ditartrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(−)-Nicotine hydrogen tartrate salt, (−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H14N2 · 2C4H6O6
Numéro CAS:
65-31-6
Poids moléculaire :
462.41
Numéro CE :
200-607-2
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

nicotine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CN1CCC[C@H]1C2=CC=CN=C2.C

InChI

1S/C10H14N2.CH4/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;/h2,4,6,8,10H,3,5,7H2,1H3;1H4/t10-;/m0./s1

Clé InChI

RYYKFQGHMYGLEL-PPHPATTJSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nicotine ditartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001023

Nicotine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001425

Nicotine ditartrate dihydrate, European Pharmacopoeia (EP) Reference Standard

1463304

Nicotine bitartrate dihydrate, United States Pharmacopeia (USP) Reference Standard

1327408

6-Hydroxynicotinic acid, United States Pharmacopeia (USP) Reference Standard

1463371

Nicotine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1463337

Nicotine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1463382

Nicotine Related Compound G, United States Pharmacopeia (USP) Reference Standard

1463326

Nicotine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463348

Nicotine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1463360

Nicotine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1463359

Nicotine Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP822

Nicotine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP821

(−)-Nicotine hydrogen tartrate salt dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2533

Nicotine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2470

6-Hydroxynicotinic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3060

Nicotine Related Compound A/EP Impurity A, pharmaceutical secondary standard, certified reference material

PHR3061

Nicotine Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3063

Nicotine Related Compound F, pharmaceutical secondary standard, certified reference material

PHR3064

Nicotine Related Compound G, pharmaceutical secondary standard, certified reference material

Pictogrammes

Skull and crossbonesHealth hazardEnvironment
GHS06,GHS08,GHS09

Mention d'avertissement

Danger

Mentions de danger

H301,H319,H330,H361d,H411

Classification des risques

Acute Tox. 2 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

289.8 °F

Point d'éclair (°C)

143.2 °C

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

(−)-Nicotine PESTANAL®, analytical standard

Supelco

36733

(−)-Nicotine

(±)-Nicotine ≥99% (TLC), liquid

Sigma-Aldrich

N0267

(±)-Nicotine

(−)-nicotine solution 1.0 mg/mL, analytical standard, for drug analysis

Supelco

N5511

(−)-nicotine solution

(-)-Nicotine for synthesis

Sigma-Aldrich

8.20877

(-)-Nicotine

Gabriel Quiroz et al.
Frontiers in pharmacology, 10, 1429-1429 (2019-12-19)
Brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family of pentameric acetylcholine-gated cation channels, have been suggested as molecular targets for the treatment of alcohol abuse and dependence. Here, we examined the effect of the competitive nAChR antagonist UFR2709 on the
José-Rubén García-Montes et al.
Molecular neurobiology, 56(6), 4037-4050 (2018-09-28)
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor type 5 (mGluR5) antagonists. Further, the onset of dyskinesia is
Elizabeth B Rex et al.
SLAS discovery : advancing life sciences R & D, 22(2), 155-165 (2016-10-30)
Cellular signaling is in part regulated by the composition and subcellular localization of a series of protein interactions that collectively form a signaling complex. Using the α7 nicotinic acetylcholine receptor (α7nAChR) as a proof-of-concept target, we developed a platform to
Xueliang Shang et al.
Molecular neurobiology, 54(6), 4644-4658 (2016-07-14)
The aim of this study was to examine if nicotine was able to improve cognition deficits in a mouse model of chronic mild stress. Twenty-four male C57BL/6 mice were divided into three groups: control, stress, and stress with nicotine treatment.
Manal A Bakathir et al.
Saudi medical journal, 37(10), 1127-1135 (2016-09-22)
To investigate the effects of nicotine on orthodontic tooth movement and accompanying histological and immunohistochemical changes in rats. An experimental study conducted at King Abdulaziz University, Jeddah, Saudi Arabia between 2013 and 2014. Thirty-two rats randomly divided into 4 groups.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique